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Ultrasound is an exciting theranostic modality that plays a criti-
cal role in diagnostic and treatment of various diseases [1, 2]. Ow-
ing to its non-invasive nature, acceptable safety, low cost and easy 
handling, ultrasonography is the second-most prescribed diagnostic 
modality by the clinicians after traditional x-ray radiography. Besides 
the diagnostic applications, ultrasound has attracted growing interest 
in cancer treatment. Following the thermal and mechanical interac-
tions of acoustic waves with tissue, efficient and new approaches for 
cancer hyperthermia and chemotherapy have been recently suggested 
[3].
In recent years, with emergence of various nanoparticles and their 
different applications in the field of cancer, nanotechnology has pre-
sented great potentials to revolutionize conventional methods of can-
cer therapy and diagnosis [4, 5].  Herein, we briefly review several 
potential applications of ultrasound in cancer nanotechnology.
Nano-Ultrasound Hyperthermia: Ultrasound, as an external 
source for hyperthermia, offers some intrinsic advantages over other 
heating sources, such as electromagnetic waves or laser. Heat induced 
by ultrasound can be remotely focused to any depth inside the body. 
Current ultrasound based thermo-ablation procedures use high inten-
sity focused ultrasound (HIFU) devices to induce a rapid cell death 
in small regions of tissue for treatment of both benign and malignant 
diseases. Uterine fibroids, benign prostatic hyperplasia, prostate can-
cer, breast cancer, brain tumors, and liver and kidney malignancies 
are the main diseases in which HIFU plays a critical therapeutic role. 
Due to small volume of ablated tissue in the focal region of a focused 
ultrasound field, the exposure time must be elongated to treat large 
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tumors. This might rises the unwanted thermal injuries to the surrounding healthy tissues [3]. 
At the moment, few studies have demonstrated that various nanoparticles such as gold 
nanoparticles (AuNPs), magnetic nanoparticles (MNPs) and silicon nanoparticles (SiNPs) of-
fer great sonosensitizing effects [6-8]. Expectedly, if the tumor is preferentially embedded 
with these nanostructures and subsequently exposed by ultrasound, selective thermal ablation 
of the tumor may be highly achievable. Furthermore, the power and duration of ultrasound 
needed to achieve enough temperature rise in ultrasound hyperthermia can be reduced in the 
presence of nanoparticles. Accordingly, a promising targeted hyperthermia being established 
through taking the intrinsic advantages of ultrasound as an energy source in combination with 
acoustically activated nanomaterials.
Ultrasound assisted drug delivery: Another application of ultrasound in cancer nanotech-
nology refers to the area of controlled drug release [9]. In conventional chemotherapy, anti-
cancer drugs are systemically distributed throughout the body and do not sufficiently reach 
the target tissue. As a result, in order to achieve desired therapeutic dose at the target site, 
high concentration of drugs must be administrated which is not clinically reasonable due to 
normal tissue complexity. An appropriate strategy to obtain adequate drug concentration at the 
tumor site is provided through encapsulation of drugs into nanocarriers and utilizing triggered 
mechanisms to facilitate drug release [10]. Pressure variation, acoustic streaming, cavitation 
and local hyperthermia are the main reasons which trigger or may accelerate the process of ul-
trasound mediated drug delivery. Today, various nanocarrier formulations such as liposomes, 
micelles, microbubbles have specially designed for ultrasound assisted drug delivery [11]. For 
example, focused ultrasound in combination with circulating microbubbles provide a nonin-
vasive strategy for local and transient blood-brain barrier disruption to attain a targeted drug 
delivery in the central nervous system.
Nano-Ultrasonography: To promote the detection limit of ultrasound imaging, ultrasound 
enhanced-contrast agents (UECAs) that can preferentially accumulate into the target tissue 
and amplify the ultrasound signal have been recently developed [12]. UECAs may enhance 
the resolution of ultrasound images and improve lesion delineation, characterization and eval-
uation the response to a treatment modality. Generally, UECAs are based on gas-filled micro-
bubble, nanobubble, hollow structure or gas-generating particles. Attaching specific ligands 
to the UECAs surfaces allow them to selectively bind to intravascular target and makes ultra-
sound molecular imaging feasible. These UECAs have optimal acoustic responses that makes 
a difference between ultrasonic properties and then obtained ultrasound signals of targeted 
and non-targeted tissue. Owing to their small size, nano-sized UECA possess enhanced tumor 
accumulation relative to micro-sized UECAs, due to the enhanced permeability and retention 
(EPR) effect. Therefore, nano-sized UECAs are thought to be elegant for tumor site detection 
124
J Biomed Phys Eng 2016; 6(3)
www.jbpe.org
upon systemic delivery [13, 14]. 
Eventually, ultrasound in combination with cancer nanotechnology has recently yielded sig-
nificant breakthrough in cancer diagnosis and therapy and seems to present more achieve-
ments so that such a combination may successfully translate into clinic in the future.
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